Dinesh Doval

Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced/metastatic triple-negative breast cancer

David Miles, Joseph Gligorov, Fabrice André et al. · Annals of Oncology · 2021 · 689 citations · Full text

Reduced graphene oxide modified smart conducting paper for cancer biosensor

Saurabh Kumar, Suveen Kumar, Saurabh Srivastava et al. · Biosensors and Bioelectronics · 2015 · 172 citations

Materials Science, Graphene Nanomeshes, Graphene Quantum Dot +4

Maintenance capecitabine and bevacizumab versus bevacizumab alone after initial first-line bevacizumab and docetaxel for patients with HER2-negative metastatic breast cancer (IMELDA): a randomised, open-label, phase 3 trial

Joseph Gligorov, Dinesh Doval, José Bines et al. · The Lancet Oncology · 2014 · 126 citations

Breast Oncology, Oncology, Maintenance Capecitabine +7

Antitumor Activity and Safety of Tivozanib (AV-951) in a Phase II Randomized Discontinuation Trial in Patients With Renal Cell Carcinoma

Dmitry Nosov, Brooke Esteves, Oleg Lipatov et al. · Journal of Clinical Oncology · 2012 · 126 citations · Full text

Clinical benefit of INCB7839, a potent and selective ADAM inhibitor, in combination with trastuzumab in patients with metastatic HER2+ breast cancer.

R. C. Newton, E C Bradley, Richard S. Levy et al. · Journal of Clinical Oncology · 2010 · 44 citations

Breast Oncology, Immunology, Pharmacotherapy +17